Nutex Health Inc SEC Filings

Nutex Health Inc. (NUTX) reported that it has released its financial and operating results for the third quarter ended September 30, 2025. The company announced these results on November 19, 2025 and made them available through a press release.

The press release is furnished as Exhibit 99.1 to this current report on Form 8-K, and is designated as furnished rather than filed under securities laws, meaning it is not automatically incorporated into other securities offerings or filings unless expressly stated.

Nutex Health Inc. reported a sharp turnaround for the quarter ended September 30, 2025, with total revenue of $267.8 million versus $78.8 million a year earlier and net income attributable to Nutex of $55.4 million compared with a loss of $8.8 million. The hospital division drove most of the growth, generating $260.2 million in quarterly revenue and $700.5 million for the first nine months, up from $199.4 million in the prior-year period, while population health revenue was stable.

For the first nine months of 2025, total revenue rose to $723.6 million from $222.3 million, and net income attributable to Nutex improved to $59.0 million from a loss of $9.5 million. Basic earnings per share were $8.27 for the quarter and $9.63 year-to-date. Cash and cash equivalents increased to $166.0 million from $40.6 million at December 31, 2024, supported by $177.7 million of net cash from operating activities. Results include substantial non-cash stock-based compensation of $119.6 million year-to-date, largely tied to obligations for under-construction and ramping hospitals, and growing arbitration-related accruals under the No Surprises Act.

Nutex Health Inc. reported that it has announced its financial and operating results for the second quarter ended June 30, 2025. The company is sharing these results through a press release dated November 18, 2025, which is furnished as Exhibit 99.1. The company states that this results information, including the exhibit, is being furnished rather than filed under securities laws and will only be incorporated into other documents if expressly stated there.

Nutex Health Inc. reports sharply higher results for the quarter ended June 30, 2025, with total revenue rising to $243.985 million from $76.082 million a year earlier, driven mainly by hospital division revenue of $236.302 million. Gross profit increased to $124.924 million, and operating income climbed to $33.679 million. However, heavy stock-based compensation of $78.747 million, largely tied to obligations for under-construction and ramping hospitals, led to a net loss attributable to Nutex of $17.697 million for the quarter, even though consolidated net income was $16.144 million due to substantial earnings allocated to noncontrolling interests. For the first six months of 2025, revenue reached $455.774 million and net income attributable to Nutex was $3.520 million, with cash and cash equivalents increasing to $96.733 million. The company also recorded $68.785 million of accrued arbitration expenses related to No Surprises Act reimbursement disputes and disclosed new legal challenges over stock issuance terms.

Nutex Health Inc. reported that it has released its financial and operating results for the first quarter ended March 31, 2025. The company announced these results on November 18, 2025 and made them available through a press release furnished as an exhibit to this report. The press release, dated November 14, 2025, is provided as Exhibit 99.1 and contains the detailed figures and operational updates for the quarter.

The company also clarified that the information in this results announcement, including the press release, is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.

Nutex Health Inc. filed an amended Q1 2025 report to restate its financial statements and internal control conclusions. The company reclassified $20.7 million of non‑cash stock‑based compensation obligations tied to under‑construction and ramping hospitals from equity to liabilities, and made additional reclassifications including $3.5 million of related‑party payables to equity, $2.9 million from cash to restricted short‑term investments, and a $2.4 million income tax accrual adjustment. As a result, total liabilities as of March 31 2025 increased by $19.6 million (4.0%), equity decreased by $19.6 million (7.1%), and net income for the quarter rose by $6.6 million (14.9%) to $50.8 million. Basic earnings per share increased to $3.74 and diluted earnings per share to $3.33. The company states these changes are non‑cash and did not materially affect revenue, liquidity, debt, operating cash flow, adjusted EBITDA or patient volumes. Management concluded a previously identified material weakness in internal control over financial reporting remains unresolved as of March 31 2025, and has engaged an accounting firm to help remediate it.

Nutex Health Inc. filed a current report to announce that it has released its financial and operating results for the fourth quarter and full year ended December 31, 2024. The results are provided in a press release dated November 18, 2025, which is furnished as Exhibit 99.1 to this report. The company also clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.

Nutex Health Inc. filed an amended Annual Report on Form 10-K/A to restate its consolidated financial statements for the year ended December 31, 2024 and update related disclosures. The restatement primarily reclassifies $16.4 million of non‑cash stock‑based compensation obligations for under‑construction and ramping hospitals from equity to liabilities, in line with ASC 718 and ASC 480, and incorporates several immaterial reclassifications. As a result, total liabilities at December 31, 2024 increased by $13.4 million (2.9%), total equity decreased by $13.4 million (6.6%), and net income for 2024 declined by about $0.5 million (0.5%). Diluted earnings per share decreased by $0.02 to $9.69, and basic earnings per share decreased by $0.02 to $10.23. The company reports that these non‑cash adjustments did not materially affect revenue, liquidity, debt levels, operating cash flow, adjusted EBITDA or patient volumes, but it has identified an additional material weakness in internal control over financial reporting and has engaged external advisors to help remediate its control environment.

Nutex Health Inc. filed a Form 12b-25 to notify that its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will be filed late. The company says it cannot meet the deadline without unreasonable effort and expense because it must first complete and file previously announced restatements of its 2024 Form 10-K and March 31, 2025 Form 10-Q, as well as the delayed June 30, 2025 Form 10-Q. Nutex Health received a Nasdaq notice on August 20, 2025 for not timely filing the June 30, 2025 Form 10-Q and obtained an extension to December 12, 2025, after which Nasdaq staff may issue a delisting notice if the report is still outstanding. The company also indicates that a significant change in results of operations versus the prior year is expected, with details referenced in an earlier Form 8-K, and it cautions that there is no assurance on the exact timing of the delayed filings.